CryoPort (NASDAQ:CYRX) Insider Edward Zecchini Sells 2,014 Shares

CryoPort, Inc. (NASDAQ:CYRX) insider Edward Zecchini sold 2,014 shares of CryoPort stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $8.00, for a total value of $16,112.00. Following the transaction, the insider owned 109,719 shares of the company’s stock, valued at $877,752. The trade was a 1.80% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

CryoPort Stock Up 4.5%

Shares of NASDAQ CYRX opened at $8.36 on Wednesday. The business’s 50 day moving average price is $9.19 and its two-hundred day moving average price is $9.36. The company has a market cap of $416.83 million, a PE ratio of 6.33 and a beta of 1.69. CryoPort, Inc. has a twelve month low of $4.63 and a twelve month high of $11.45.

CryoPort (NASDAQ:CYRX) last issued its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.02). CryoPort had a net margin of 42.35% and a negative return on equity of 8.22%. The company had revenue of $45.45 million during the quarter, compared to the consensus estimate of $42.92 million. As a group, research analysts anticipate that CryoPort, Inc. will post -0.99 EPS for the current fiscal year.

Key Headlines Impacting CryoPort

Here are the key news stories impacting CryoPort this week:

• Positive Sentiment: Analyst upgrade/target increase: Needham raised its target to $13 and reiterated a “buy” view, which supports upside expectations and may be helping the stock’s strength. MarketBeat CYRX Analyst Coverage
• Neutral Sentiment: Mixed Q4 results remain in the backdrop — revenue beat consensus but EPS missed modestly; investors may be parsing near-term profitability versus top-line growth. MarketBeat CYRX Earnings Summary
• Neutral Sentiment: Institutional activity: several small/new stakes were reported (various funds adding modest positions); institutional ownership remains high (~93%), which can reduce float volatility but also concentrate moves. MarketBeat CYRX Institutional Ownership
• Negative Sentiment: Insider selling — CEO Jerrell Shelton sold 7,918 shares at an average $8.00 on Mar 16 (ownership decreased ~0.75%), a signal some investors view as negative. CEO SEC Filing
• Negative Sentiment: Significant CFO selling — Robert Stefanovich disclosed a larger sale on Mar 12 of 38,700 shares (~13.15% of his prior holding) and additional sales on Mar 16 (2,743 shares). Large insider liquidation by a senior finance officer can weigh on sentiment. CFO SEC Filing
• Negative Sentiment: Additional insider sales: Mark W. Sawicki sold 3,235 shares and Edward J. Zecchini sold 2,014 shares on Mar 16 — cumulatively these insider dispositions add to negative optics even if dollar amounts are modest. Insider SEC Filings

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. Needham & Company LLC boosted their price target on CryoPort from $12.00 to $13.00 and gave the company a “buy” rating in a research note on Wednesday, March 4th. Wall Street Zen downgraded shares of CryoPort from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of CryoPort in a report on Monday, December 29th. Eight analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $12.94.

Institutional Trading of CryoPort

Several hedge funds and other institutional investors have recently made changes to their positions in the company. AQR Capital Management LLC raised its position in CryoPort by 285.5% during the 1st quarter. AQR Capital Management LLC now owns 262,596 shares of the company’s stock worth $1,597,000 after purchasing an additional 194,482 shares during the last quarter. Savant Capital LLC acquired a new stake in shares of CryoPort in the second quarter valued at about $93,000. ProShare Advisors LLC bought a new position in shares of CryoPort during the second quarter worth about $75,000. Geode Capital Management LLC raised its position in shares of CryoPort by 7.8% during the second quarter. Geode Capital Management LLC now owns 1,203,061 shares of the company’s stock worth $8,977,000 after acquiring an additional 87,418 shares during the last quarter. Finally, Creative Planning acquired a new position in shares of CryoPort in the second quarter worth approximately $96,000. 92.90% of the stock is currently owned by institutional investors.

About CryoPort

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.